Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0633 in patients with COPD
2006-005096-17Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing MK-0633 with Placebo (2 arms). Primary endpoint: Pre-dose (trough) FEV1 over 12 weeks. Started Oct 2006; status: completed.
02
Drugs
MK-633
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2006-005096-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005096-17.